Traders purchased shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading on Thursday. $57.67 million flowed into the stock on the tick-up and $36.52 million flowed out of the stock on the tick-down, for a money net flow of $21.15 million into the stock. Of all equities tracked, Eli Lilly and had the 19th highest net in-flow for the day. Eli Lilly and traded down ($0.33) for the day and closed at $79.78

Several brokerages have recently issued reports on LLY. Morgan Stanley restated a “hold” rating and issued a $88.00 price objective on shares of Eli Lilly and in a research note on Saturday, June 4th. Leerink Swann restated a “buy” rating on shares of Eli Lilly and in a research note on Sunday, June 26th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a research note on Friday, July 29th. BMO Capital Markets restated a “buy” rating and issued a $94.00 price objective on shares of Eli Lilly and in a research note on Wednesday, July 27th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating on shares of Eli Lilly and in a research report on Thursday, May 26th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $96.35.

The stock has a 50-day moving average of $80.82 and a 200-day moving average of $75.97. The company has a market capitalization of $83.62 billion and a P/E ratio of 34.08.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.86. During the same period last year, the company posted $0.90 earnings per share. The company had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Co. will post $3.59 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 2.58%. The ex-dividend date of this dividend is Thursday, August 11th.

In other news, insider Donald A. Zakrowski sold 1,213 shares of the stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $83.16, for a total transaction of $100,873.08. Following the sale, the insider now directly owns 1,300 shares of the company’s stock, valued at approximately $108,108. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jackson P. Tai bought 5,773 shares of Eli Lilly and stock in a transaction dated Monday, August 15th. The shares were bought at an average cost of $80.43 per share, for a total transaction of $464,322.39. Following the completion of the acquisition, the director now owns 42,306 shares in the company, valued at approximately $3,402,671.58. The disclosure for this purchase can be found here.

Other hedge funds recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. raised its stake in Eli Lilly and by 3.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 3,586,902 shares of the company’s stock valued at $302,233,000 after buying an additional 129,362 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Eli Lilly and by 45.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 87,000 shares of the company’s stock valued at $7,331,000 after buying an additional 27,275 shares in the last quarter. King Luther Capital Management Corp increased its stake in shares of Eli Lilly and by 1.4% in the fourth quarter. King Luther Capital Management Corp now owns 186,246 shares of the company’s stock valued at $15,693,000 after buying an additional 2,562 shares in the last quarter. Budros Ruhlin & Roe Inc. increased its stake in shares of Eli Lilly and by 0.4% in the fourth quarter. Budros Ruhlin & Roe Inc. now owns 27,156 shares of the company’s stock valued at $2,288,000 after buying an additional 121 shares in the last quarter. Finally, Calvert Investment Management Inc. increased its stake in shares of Eli Lilly and by 24.1% in the fourth quarter. Calvert Investment Management Inc. now owns 51,507 shares of the company’s stock valued at $4,340,000 after buying an additional 10,005 shares in the last quarter.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.